亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Real-Time Liquid Biopsy Cancer Diagnosis and Monitoring

技术应用
Early detection and real-time monitoring ofcancer DNA from non-invasive liquid biopsy samplesTumor tissue-of-origin determinationCancer sub-type classificationKey applications will be in oncology, forensics, genetic profiling, andenvironmental testing
详细技术说明
Non-invasive liquid biopsy to diagnose specific cancer subtypesusing genome-wide DNA methylation and transcription factor profiles
*Abstract

DNA methylation profiles are highly cell-typespecific and are disrupted in many diseases, including cancer. Here weintroduce Cell-Free Methylated DNA Immunoprecipitation and High-throughputSequencing (cfMeDIP-seq), a robust picogram - nanogram input method suitablefor genome-wide methylome analysis of cell-free DNA (cfDNA). Current detectionmethods from solid tumors and liquid samples are impractical due to their insensitiveand non-specific diagnoses. Invasivebiopsies can also lead to tissue damage and increased metastasis.  The disclosed technology utilizes cfDNAisolated from cancer patients to subtype cancer and determine the tissue oforigin. Therefore, cfMeDIPseq could beused to detect circulating tumor DNA, to infer tissue-of-origin and classifycancer patients. This technology reducesthe health impact on patients during biopsies and significantly improves thedetection limits 10X over previous liquid biopsies using DNA markers as used inother PCR-based systems. The detection limits are sufficient to be appliedacross multiple indications.


Tumorsare a complex problem that require stringent monitoring (Junttila and deSauvage. Nature). cfMeDIP-seq wasperformed in circulating cfDNA from patient blood samples. For the samepatients, cfMeDIP-seq was also performed in circulating cfDNA from the blood of15 age- and gender-matched healthy donors.

*Principal Investigation

Dr. Daniel De Carvalho, Princess Margaret Cancer Centre,University Health Network

*Publications
Clinical Applications of Circulating Tumor Cells andCirculating Tumor DNA as Liquid Biopsy.Alix-Panabières C, et al. 2016 May;6(5):479-91. doi:10.1158/2159-8290.CD-15-1483. Review.Influence of tumour micro-environment heterogeneityon therapeutic response.Junttila and de Sauvage. Nature.2013, 501:346-354
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备